Reviewed by Michael Gill, B. Sc.
25 Hnscc Clinical Trials Near Me
Top Hospitals for Hnscc Clinical Trials
Image of Dana Farber Cancer Institute in Massachusetts.
Dana Farber Cancer Institute
Boston
7Active Trials
27All Time Trials for Hnscc
2006First Hnscc Trial
Image of UPMC Hillman Cancer Center in Pennsylvania.
UPMC Hillman Cancer Center
Pittsburgh
6Active Trials
27All Time Trials for Hnscc
2016First Hnscc Trial
Top Treatments for Hnscc Clinical Trials
Treatment Name
Active Hnscc Clinical Trials
All Time Trials for Hnscc
First Recorded Hnscc Trial
Pembrolizumab
9
112
2015
NBTXR3
2
2
2019
Tipifarnib
2
2
2018
Phase 1 Dose Escalation
1
1
2022
Setanaxib
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Hnscc
Treatment
Year
Sponsor
Pembrolizumab
2020
Merck Sharp & Dohme LLC
ALKS 4230
2020
Alkermes, Inc.
ABBV-368
2020
AbbVie
IRX 2
2019
H. Lee Moffitt Cancer Center and Research Institute
Zirconium Zr-89 Panitumumab
2019
Eben Rosenthal
Copanlisib
2018
Bayer
GEN-009 Adjuvanted Vaccine
2018
Genocea Biosciences, Inc.
XmAb20717
2018
Xencor, Inc.
Cetuximab
2018
Memorial Sloan Kettering Cancer Center
Ficlatuzumab
2017
University of Arizona

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. https://pubmed.ncbi.nlm.nih.gov/333003722 Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 Dec;161(6):1813-1829. doi: 10.1053/j.gastro.2021.09.059. Epub 2021 Oct 2. Review. https://pubmed.ncbi.nlm.nih.gov/346068463 Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kalpha inhibition in controlling tumor growth. Int J Cancer. 2019 Oct 15;145(8):2100-2106. doi: 10.1002/ijc.32009. Epub 2018 Dec 18. Erratum In: Int J Cancer. 2020 Jan 1;146(1):E23. https://pubmed.ncbi.nlm.nih.gov/304682434 Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, Ferris RL, Delgoffe GM. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021 May;9(5). pii: e002088. doi: 10.1136/jitc-2020-002088. https://pubmed.ncbi.nlm.nih.gov/339861235 Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, Wambua D, Kong L, Behera P, Jacques J, Goshert C, Ball M, Colthart A, Finer MH, Hayes MW, Feau S, Kennedy EM, Lerner L, Quéva C. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity. Cancer Immunol Res. 2021 Mar;9(3):291-308. doi: 10.1158/2326-6066.CIR-20-0609. Epub 2020 Dec 22. https://pubmed.ncbi.nlm.nih.gov/333552296 Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):883-892. doi: 10.1016/S1470-2045(21)00136-4. Epub 2021 May 11. https://pubmed.ncbi.nlm.nih.gov/339895597 Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth. Int J Cancer. 2019 Oct 15;145(8):2100-2106. doi: 10.1002/ijc.32009. Epub 2018 Dec 18. Erratum in: Int J Cancer. 2020 Jan 1;146(1):E23. https://pubmed.ncbi.nlm.nih.gov/304682438 Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20. https://pubmed.ncbi.nlm.nih.gov/350650589 Seiwert TY, Shen C, Frakes JM, Hu Y, Niu J, Weiss J, Caudell JJ, Barsoumian HB, Thariat JO, Bonvalot S, Papai Z, Cortez MA, Zhang P, Jameson K, Said P, Paris S, Welsh JW. Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside. Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S68-S69. doi: 10.1016/j.ijrobp.2021.07.170. https://pubmed.ncbi.nlm.nih.gov/3470060910 Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, Wambua D, Kong L, Behera P, Jacques J, Goshert C, Ball M, Colthart A, Finer MH, Hayes MW, Feau S, Kennedy EM, Lerner L, Queva C. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity. Cancer Immunol Res. 2021 Mar;9(3):291-308. doi: 10.1158/2326-6066.CIR-20-0609. Epub 2020 Dec 22. https://pubmed.ncbi.nlm.nih.gov/33355229